-
Dec 2013
IL-2 therapy in type 1 diabetes: "Trials" and tribulations.
Clin ImmunolLong SA, Buckner JH, Greenbaum CJ -
Aug 2013
Intersection between genetic polymorphisms and immune deviation in type 1 diabetes.
Curr Opin Endocrinol Diabetes ObesLong SA, Buckner JH -
Jun 2013
Evaluation of in vivo T cell kinetics: use of heavy isotope labelling in type 1 diabetes.
Clin Exp ImmunolBollyky JB, Long SA, Fitch M, Bollyky PL, Rieck M, Rogers R, Samuels PL, Sanda S, Buckner JH, Hellerstein MK, Greenbaum CJ -
Jan 2013
In active relapsing-remitting multiple sclerosis, effector T cell resistance to adaptive T(regs) involves IL-6-mediated signaling.
Sci Transl MedSchneider A, Long SA, Cerosaletti K, Ni CT, Samuels P, Kita M, Buckner JH -
Sep 2012
Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs β-cell function.
DiabetesLong SA, Rieck M, Sanda S, Bollyky JB, Samuels PL, Goland R, Ahmann A, Rabinovitch A, Aggarwal S, Phippard D, Turka LA, Ehlers MR, Bianchine PJ, Boyle KD, Adah SA, Bluestone JA, Buckner JH, Greenbaum CJ, Diabetes TrialNet and the Immune Tolerance Network. -
Oct 2011
Low-dose antigen promotes induction of FOXP3 in human CD4+ T cells.
J ImmunolLong SA, Rieck M, Tatum M, Bollyky PL, Wu RP, Muller I, Ho JC, Shilling HG, Buckner JH -
Sep 2011
CD4+FOXP3+ T regulatory cells in human autoimmunity: more than a numbers game.
J ImmunolLong SA, Buckner JH -
May 2011
ECM components guide IL-10 producing regulatory T-cell (TR1) induction from effector memory T-cell precursors.
Proc Natl Acad Sci U S ABollyky PL, Wu RP, Falk BA, Lord JD, Long SA, Preisinger A, Teng B, Holt GE, Standifer NE, Braun KR, Xie CF, Samuels PL, Vernon RB, Gebe JA, Wight TN, Nepom GT -
Mar 2011
An autoimmune-associated variant in PTPN2 reveals an impairment of IL-2R signaling in CD4(+) T cells.
Genes ImmunLong SA, Cerosaletti K, Wan JY, Ho JC, Tatum M, Wei S, Shilling HG, Buckner JH -
May 2010
Th1 cytokines promote T-cell binding to antigen-presenting cells via enhanced hyaluronan production and accumulation at the immune synapse.
Cell Mol ImmunolBollyky PL, Evanko SP, Wu RP, Potter-Perigo S, Long SA, Kinsella B, Reijonen H, Guebtner K, Teng B, Chan CK, Braun KR, Gebe JA, Nepom GT, Wight TN -
Feb 2010
Defects in IL-2R signaling contribute to diminished maintenance of FOXP3 expression in CD4(+)CD25(+) regulatory T-cells of type 1 diabetic subjects.
DiabetesLong SA, Cerosaletti K, Bollyky PL, Tatum M, Shilling H, Zhang S, Zhang ZY, Pihoker C, Sanda S, Greenbaum CJ, Buckner JH -
Aug 2009
CD44 costimulation promotes FoxP3+ regulatory T cell persistence and function via production of IL-2, IL-10, and TGF-beta.
J ImmunolBollyky PL, Falk BA, Long SA, Preisinger A, Braun KR, Wu RP, Evanko SP, Buckner JH, Wight TN, Nepom GT -
Feb 2009
Functional islet-specific Treg can be generated from CD4+CD25- T cells of healthy and type 1 diabetic subjects.
Eur J ImmunolLong SA, Walker MR, Rieck M, James EA, Kwok WW, Sanda S, Pihoker C, Nepom GT, Buckner JH -
Jun 2008
Combination of rapamycin and IL-2 increases de novo induction of human CD4(+)CD25(+)FOXP3(+) T cells.
J AutoimmunLong SA, Buckner JH -
Sep 2004
Optimization of human T-cell expansion ex vivo using magnetic beads conjugated with anti-CD3 and Anti-CD28 antibodies.
J ImmunotherKalamasz D, Long SA, Taniguchi R, Buckner JH, Berenson RJ, Bonyhadi M